Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180219002

Enrollment

321

Registered

2018-02-19

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sputum conversion in pulmonary tuberculosis Sputum conversion&#44

Interventions

Simvastatin (10 mg) 1 capsule po hs,Simvastatin (20 mg) 1 capsule po hs,Placebo 1 capsule po hs

Experimental Drug,Experimental Drug,Placebo Comparator No treatment

10 mg simvastatin,20 mg simvastatin,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: - Patients with pulmonary tuberculosis confirmed by acid-fast bacilli (AFB) in sputum - 20 years of age or older - Body weight 50 kilograms or more

Exclusion criteria

Exclusion criteria: - Serum creatinine > 1.6 mg/dl - AST and/or ALT > 3-fold upper limit of normal - Neoplastic disease - Hypothyroidism - Known hypersensitivity to simvastatin - Pregnant and breastfeeding women

Design outcomes

Primary

Measure	Time frame
Sputum conversion 2 months Sputum AFB	—

Secondary

Measure	Time frame
Adverse reacttions 2 months Record	—

Countries

Thailand

Contacts

Public ContactThammasorn Jeeraaumponwat

Khon Kaen Hospital

t.jeeraaumponwat@cpird.in.th086-964-2222

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026

Simvastatin and sputum conversion in pulmonary tuberculosis: a double&#45;blinded randomized controlled trial